• Home
  • Search Results
  • Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.

Nature communications (2015-04-01)
Shahul Hameed P, Suresh Solapure, Vikas Patil, Philipp P Henrich, Pamela A Magistrado, Sowmya Bharath, Kannan Murugan, Pavithra Viswanath, Jayashree Puttur, Abhishek Srivastava, Eknath Bellale, Vijender Panduga, Gajanan Shanbag, Disha Awasthy, Sudhir Landge, Sapna Morayya, Krishna Koushik, Ramanatha Saralaya, Anandkumar Raichurkar, Nikhil Rautela, Nilanjana Roy Choudhury, Anisha Ambady, Radha Nandishaiah, Jitendar Reddy, K R Prabhakar, Sreenivasaiah Menasinakai, Suresh Rudrapatna, Monalisa Chatterji, María Belén Jiménez-Díaz, María Santos Martínez, Laura María Sanz, Olivia Coburn-Flynn, David A Fidock, Amanda K Lukens, Dyann F Wirth, Balachandra Bandodkar, Kakoli Mukherjee, Robert E McLaughlin, David Waterson, Lyn Rosenbrier-Ribeiro, Kevin Hickling, V Balasubramanian, Peter Warner, Vinayak Hosagrahara, Adam Dudley, Pravin S Iyer, Shridhar Narayanan, Stefan Kavanagh, Vasan K Sambandamurthy
ABSTRACT

The widespread emergence of Plasmodium falciparum (Pf) strains resistant to frontline agents has fuelled the search for fast-acting agents with novel mechanism of action. Here, we report the discovery and optimization of novel antimalarial compounds, the triaminopyrimidines (TAPs), which emerged from a phenotypic screen against the blood stages of Pf. The clinical candidate (compound 12) is efficacious in a mouse model of Pf malaria with an ED99 <30 mg kg(-1) and displays good in vivo safety margins in guinea pigs and rats. With a predicted half-life of 36 h in humans, a single dose of 260 mg might be sufficient to maintain therapeutic blood concentration for 4-5 days. Whole-genome sequencing of resistant mutants implicates the vacuolar ATP synthase as a genetic determinant of resistance to TAPs. Our studies highlight the potential of TAPs for single-dose treatment of Pf malaria in combination with other agents in clinical development.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrochloric acid, ACS reagent, 37%
Sigma-Aldrich
Toluene, anhydrous, 99.8%
Sigma-Aldrich
1,4-Dioxane, anhydrous, 99.8%
Sigma-Aldrich
Hydrochloric acid, ACS reagent, 37%
Sigma-Aldrich
N,N-Diisopropylethylamine, ReagentPlus®, ≥99%
Sigma-Aldrich
Toluene, ACS reagent, ≥99.5%
Sigma-Aldrich
Hydrogen chloride solution, 4.0 M in dioxane
Sigma-Aldrich
Hydrochloric acid solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Hydrochloric acid, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
N,N-Diisopropylethylamine, purified by redistillation, 99.5%
Sigma-Aldrich
Di-tert-butyl dicarbonate, ReagentPlus®, 99%
Sigma-Aldrich
Aluminum oxide, activated, basic, Brockmann I
Sigma-Aldrich
1,4-Dioxane, ACS reagent, ≥99.0%
Sigma-Aldrich
Toluene, suitable for HPLC, 99.9%
Sigma-Aldrich
Aluminum oxide, activated, neutral, Brockmann I
Supelco
Hydrochloric acid solution, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Aluminum oxide, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
Hydrogen chloride solution, 2.0 M in diethyl ether
Sigma-Aldrich
Di-tert-butyl dicarbonate, ≥98.0% (GC)
Supelco
Aluminum oxide, activated, neutral, Brockmann Activity I
Supelco
Hydrogen chloride – methanol solution, ~1.25 m HCl (T), for GC derivatization, LiChropur
Sigma-Aldrich
Hydrogen chloride, ReagentPlus®, ≥99%
Sigma-Aldrich
1,4-Dioxane, suitable for HPLC, ≥99.5%
Supelco
1,4-Dioxane, analytical standard
Sigma-Aldrich
Hydrochloric acid, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Sigma-Aldrich
Aluminum oxide, powder, 99.99% trace metals basis
Sigma-Aldrich
N,N-Diisopropylethylamine, 99.5%, biotech. grade
Sigma-Aldrich
Di-tert-butyl dicarbonate, ReagentPlus®, ≥99%
Sigma-Aldrich
Hydrochloric acid solution, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
1,4-Dioxane, ReagentPlus®, ≥99%